SG Americas Securities LLC Grows Position in Sutro Biopharma, Inc. (NASDAQ:STRO)

SG Americas Securities LLC lifted its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 16.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,432 shares of the company’s stock after purchasing an additional 5,770 shares during the quarter. SG Americas Securities LLC’s holdings in Sutro Biopharma were worth $74,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of STRO. The Manufacturers Life Insurance Company grew its holdings in shares of Sutro Biopharma by 27.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after purchasing an additional 7,082 shares during the period. Gladius Capital Management LP purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth $28,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth $1,512,000. Intech Investment Management LLC purchased a new position in shares of Sutro Biopharma during the 3rd quarter worth $91,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Sutro Biopharma by 16.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,995 shares of the company’s stock worth $872,000 after purchasing an additional 35,167 shares during the period. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Sutro Biopharma Price Performance

STRO stock opened at $1.74 on Friday. The firm has a market capitalization of $143.48 million, a P/E ratio of -1.08 and a beta of 1.15. The business’s 50-day moving average is $1.98 and its two-hundred day moving average is $3.10. Sutro Biopharma, Inc. has a 1 year low of $1.51 and a 1 year high of $6.13.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on STRO. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a research note on Monday, November 18th. Wedbush reissued an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a research note on Tuesday, December 10th. Wells Fargo & Company decreased their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Finally, JMP Securities reissued a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Sutro Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $11.13.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.